MED
MEDIFAST INC
12.20$
+2.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 70.7% | 75.1% | 83.6% | 85.8% | 85.9% | 79.2% | 84.9% | 77.0% | 70.5% | 72.3% | 75.4% | 78.5% | |
| 21.1% | 35.8% | 43.3% | 51.4% | 48.0% | 39.5% | 59.3% | 26.2% | 27.7% | 30.5% | 32.0% | 34.7% | |
| 45.4% | 57.2% | 63.4% | 67.7% | 59.6% | 47.6% | 63.2% | 27.5% | 27.7% | 48.4% | 57.1% | 65.1% | |
| 1.4% | 1.4% | 1.1% | 0.4% | 0.6% | 0.7% | 0.2% | 0.0% | 0.0% | 2.8% | – | – | |
| 13.6% | 11.4% | 15.1% | 13.2% | 23.0% | 25.1% | 19.3% | 45.2% | 37.6% | 17.6% | 14.9% | 7.9% | |
| 28.9% | 24.7% | 16.3% | 12.8% | 11.7% | 13.4% | 10.0% | 14.1% | 18.1% | 21.7% | 17.1% | 15.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 30.6% | 24.5% | 20.8% | 25.6% | 35.6% | 46.1% | 43.0% | 49.2% | 51.0% | 35.0% | 26.1% | 22.6% | |
| 23.2% | 20.1% | 20.1% | 25.5% | 35.6% | 40.8% | 40.3% | 42.6% | 44.6% | 29.8% | 22.6% | 16.7% | |
| 0.2% | 0.2% | 0.0% | 0.0% | 0.0% | 1.6% | 1.3% | 1.6% | 1.8% | 1.9% | 2.2% | 1.8% | |
| 10.5% | 9.6% | 7.9% | 9.5% | 11.2% | 11.6% | 13.1% | 17.8% | 18.6% | 12.6% | 8.1% | 5.9% | |
| 0.2% | 0.0% | 0.6% | 0.0% | – | – | – | – | – | – | – | – | |
| 69.4% | 75.5% | 79.2% | 74.4% | 64.4% | 53.9% | 57.0% | 50.8% | 49.0% | 65.0% | 73.9% | 77.4% | |
| 68.1% | 75.5% | 77.1% | 71.1% | 77.5% | 86.7% | 55.9% | 47.8% | 44.2% | 56.4% | 62.2% | 61.6% | |
| 11.0% | 10.3% | 9.9% | 8.3% | 7.1% | 6.2% | 4.3% | 3.0% | 3.6% | 3.5% | 3.9% | 4.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.